PALI Oppenheimer initiated coverage of Palisade Bio with an Outperform rating and $8 price target. The firm believes Palisade Bio offers inv
PALI Oppenheimer initiated coverage of Palisade Bio with an Outperform rating and $8 price target. The firm believes Palisade Bio offers investors an attractive way to participate in the large/growing inflammatory bowel disease space as the company's therapeutic development programs move toward their first Phase 2 read